Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2001

View Archived Issues

Bio-Technology General to acquire Myelos

FDA requests additional information for Dermagraft PMA

Merck purchases Aurora technology for drug discovery

Pharming reports operational, product and financial highlights

Atugen and G.O.T. Therapeutics to develop novel drug delivery technology

Lp-PLA2-lowering drug candidate enters clinical trials

Early March launch for new antiallergic agent from Kyowa Hakko

Toyama plans to partner development of T-705

Santen granted rights to develop and market lomerizine for ophthalmological indications

Microbial metabolite inhibits interaction between p53 and MDM2

Axcan offers company update

CA4P exerts antiangiogenic effects in animal lymphoma model

Message Pharmaceuticals and Boehringer Ingelheim enter drug discovery collaboration

Patient enrollment complete in phase III trial of oral treatment for pulmonary hypertension

Takeda will develop a compound for diabetic neuropathy originating at Welfide

AN-207 selectively targets LHRH receptor-expressing ovarian cancer cells

Hemosol seeks U.K. approval of Hemolink

Studies confirm that etoricoxib is one of the most selective COX-2 inhibitors yet reported

Gilead seeks Tamiflu approval in E.U.

PowderJect and GlaxoSmithKline initiate trial with DNA vaccine for hepatitis B treatment

Isis presents new antisense oligonucleotides for cancer

Maxim's caspase inhibitor protects against liver apoptosis in preclinical study

Telomerase-inhibitory thiazolidinones designed by Geron

AstraZeneca claims neuropeptide Y antagonists and their use

Teikoku Hormone describes new treatments for estrogen-related diseases

Factor Xa inhibitors useful as anticoagulants described by Sankyo

Medarex/Biosite/Eos Biotechnology drug discovery alliance formed

ZK-807834 superior to heparin/aspirin and rTAP in conjunction with fibrinolysis following thrombosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...